Opdualag

nivolumab and relatlimab-rmbw · NIVOLUMAB 12 mg/mL; RELATLIMAB 4 mg/mL · Injection · Intravenous · E.R. Squibb & Sons, L.L.C.

NDC 00003-7125-11 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. A Class II recall hit this product in the past year (Bristol-Myers Squibb Company).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part B pays (ASP+6%)$205.51per billing unit (3 mg/1 mg)HCPCS J9298 · Jul 1, 2026
Part D plans paid (avg)$722.94per dosage unitgross, before rebates — matched by drug name · 2024
Federal ceiling (Big4)$11,261.93per package of 20MLBristol-Myers Squibb Company · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$15,730.41

Reported to Texas DSHS · 2026 annual filing · Bristol-Myers Squibb Company & Subsidiaries

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 3 mg/1 mg

$205.511

HCPCS J9298 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$4.5M

260 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 3 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $29,075.49 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: BLA761234
TE code: —
Approval date: —
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class II · OngoingOct 21, 2025
Bristol-Myers Squibb Company — Lack of Assurance of Sterility.

Manufacturers of nivolumab and relatlimab-rmbw (Injection)

Labeler	Strength	First seen	Last seen
E.R. Squibb & Sons, L.L.C.	NIVOLUMAB 12 mg/mL; RELATLIMAB 4 mg/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Opdualag — NDC 00003-7125-11," retrieved September 3, 2026, https://drugdashboards.com/drug/00003712511.

Free to cite with attribution — see how the data is put together.